Rathin Med and Innovosens collaborated to bring a new, non-invasive blood sugar monitor to market.
Rathin Med won Eureka Eurostar 3 Call 2 competition in July 2022 in collaboration with a Swedish company Innovosens securing a funding of £80,000 together from Innovate UK to get regulatory approvals and market SMASH in the UK. SMASH-Sweat Metabolite Analysis for Sports and Health, a product of Innovosens is an AI-powered non-invasive sweat wearable sensor for continuous real time monitoring of Glucose and Lactate. It has 3 components- A Microfluidic Sweat Sensor, Electronic Reader, and an App.
Diabetes UK figures from April 2023 show that 4.3 million people are now living with a diagnosis of diabetes in the UK. Also there are an additional 850,000 people living with diabetes who are yet to be diagnosed, bringing the overall UK-wide figure beyond five million. Personalised health management achieved via the SMASH device will contribute to increased wellbeing, improved physical health and lead to a more productive society.
Eureka and Innovate UK, project management platform have helped us enormously to develop and market the device. In 2024 we are aiming to market SMASH as a Health and Wellness device in the UK.
Our portfolio of work
View all
Get in touch with us
For more information on what we do or to enquire about helping fund a future project you can message or call us here
